{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:33:11Z","timestamp":1772483591346,"version":"3.50.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Abbott"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Although testosterone replacement therapy (TRT) is the preferred treatment for hypogonadism, information for patients using testosterone includes too frequent or prolonged erections as a potential side effect.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To assess the frequency and risk of priapism or related adverse events (AEs) in hypogonadal men treated with a 1% testosterone gel.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Safety and tolerability data for AndroGel 1% were assessed, including three randomized, controlled clinical trials in varying populations of hypogonadal or near hypogonadal men. Study 1 was a Phase 3 trial of AndroGel 1% 5 g, 7.5 g, or 10 g once daily for 6 months (N = 227). Study 2 was a Phase 2 trial of AndroGel 1% 7.5 g once daily titrated as needed vs. placebo for 26 weeks in men with type 2 diabetes (N = 180). Study 3 was a Phase 4 trial of AndroGel 1% 5 g once daily vs. placebo for 12 weeks in men previously unresponsive to sildenafil 100 mg monotherapy and receiving concomitant sildenafil 100 mg (N = 75). Postmarketing AndroGel pharmacovigilance reporting data from 2001 to 2011 was searched for events coded as priapism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>The incidence of priapism and\/or related symptoms reported as urogenital or reproductive system AEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the 283 men exposed to AndroGel 1% over the three trials, mean exposure ranged from 84 days to 149 days. No AEs described as priapism or related symptoms were reported in the three trials. In the postmarketing data, representing 40 million units sold, eight cases described as priapism were reported. Of the six cases with accompanying data, all were judged as possibly related to AndroGel.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Safety data from the clinical trials for AndroGel 1% did not report any cases of priapism, and its incidence in the postmarketing pharmacovigilance data is extremely low, indicating a minimal risk of inducing priapism.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jsm.12059","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T15:44:06Z","timestamp":1359042246000},"page":"1151-1161","source":"Crossref","is-referenced-by-count":12,"title":["Testosterone Replacement with 1% Testosterone Gel and Priapism: No Definite Risk Relationship"],"prefix":"10.1093","volume":"10","author":[{"given":"Arthur L.","family":"Burnett","sequence":"first","affiliation":[{"name":"Johns Hopkins University , Baltimore , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Kan-Dobrosky","sequence":"additional","affiliation":[{"name":"Abbott , Abbott Park , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Miller","sequence":"additional","affiliation":[{"name":"Abbott , Abbott Park , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,4,1]]},"reference":[{"key":"2024032601012888500_bib1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/jcem.86.2.7219","article-title":"Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging","volume":"86","author":"Harman","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032601012888500_bib2","volume-title":"Testosterone and aging: Clinical research directions","author":"Liverman","year":"2004"},{"key":"2024032601012888500_bib3","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline","volume":"95","author":"Bhasin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032601012888500_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/jcem.87.2.8201","article-title":"Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts male aging study","volume":"87","author":"Feldman","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032601012888500_bib5","volume-title":"National Prescription Audit","author":"IMS National Prescription Audit","year":"2009"},{"key":"2024032601012888500_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11930-004-0025-0","article-title":"Evolution of delivery systems for testosterone administration","volume":"1","author":"Kaufman","year":"2004","journal-title":"Curr Sex Health Rep"},{"key":"2024032601012888500_bib7","volume-title":"(testosterone) gel [prescribing information]","author":"Fortesta\u2122"},{"key":"2024032601012888500_bib8","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/j.1743-6109.2011.02265.x","article-title":"Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men","volume":"8","author":"Kaufman","year":"2011","journal-title":"J Sex Med"},{"key":"2024032601012888500_bib9","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1210\/jc.2002-021058","article-title":"AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function","volume":"88","author":"Steidle","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032601012888500_bib10","first-page":"4500","article-title":"Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men","volume":"85","author":"Swerdloff","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032601012888500_bib11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/edrv.22.3.0430","article-title":"Male sexual function and its disorders: Physiology, pathophysiology, clinical investigation, and treatment","volume":"22","author":"Kandeel","year":"2001","journal-title":"Endocr Rev"},{"issue":"suppl 2","key":"2024032601012888500_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2605.2005.00550.x","article-title":"Peripheral regulatory mechanisms in erection","volume":"28","author":"Morelli","year":"2005","journal-title":"Int J Androl"},{"key":"2024032601012888500_bib13","volume-title":"(testosterone gel) 1.62% [prescribing information]","author":"AndroGel\u00ae","year":"2011"},{"key":"2024032601012888500_bib14","volume-title":"(testosterone gel) 1% [prescribing information]","author":"AndroGel\u00ae","year":"2010"},{"key":"2024032601012888500_bib15","volume-title":"(testosterone) topical solution [prescribing information]","author":"Axiron\u00ae","year":"2010"},{"key":"2024032601012888500_bib16","volume-title":"1% (testosterone gel) [prescribing information]","author":"Testim\u00ae","year":"2009"},{"key":"2024032601012888500_bib17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1743-6109.2009.01625.x","article-title":"Priapism: Pathogenesis, epidemiology, and management","volume":"7","author":"Broderick","year":"2010","journal-title":"J Sex Med"},{"key":"2024032601012888500_bib18","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/01.ju.0000087608.07371.ca","article-title":"American Urological Association guideline on the management of priapism","volume":"170","author":"Montague","year":"2003","journal-title":"J Urol"},{"key":"2024032601012888500_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1743-6109.2011.02411.x","article-title":"Sexual health outcomes improvement in sickle cell disease: A matter of health policy?","volume":"9","author":"Burnett","year":"2012","journal-title":"J Sex Med"},{"key":"2024032601012888500_bib20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ucl.2011.02.005","article-title":"Priapism: New concepts in medical and surgical management","volume":"38","author":"Burnett","year":"2011","journal-title":"Urol Clin North Am"},{"key":"2024032601012888500_bib21","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0090-4295(01)00941-4","article-title":"Incidence of priapism in the general population","volume":"57","author":"Eland","year":"2001","journal-title":"Urology"},{"key":"2024032601012888500_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/pgmj.2005.037291","article-title":"Medical and surgical management of priapism","volume":"82","author":"Cherian","year":"2006","journal-title":"Postgrad Med J"},{"key":"2024032601012888500_bib23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-5347(05)67836-6","article-title":"Priapism as a complication of high dose testosterone therapy in a man with hypogonadism","volume":"163","author":"Zargooshi","year":"2000","journal-title":"J Urol"},{"key":"2024032601012888500_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0002-9343(88)80364-4","article-title":"Severe priapism as a complication of testosterone substitution therapy","volume":"85","author":"Zelissen","year":"1988","journal-title":"Am J Med"},{"key":"2024032601012888500_bib25","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/gerona\/60.11.1451","article-title":"Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials","volume":"60","author":"Calof","year":"2005","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2024032601012888500_bib26","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1210\/jc.2009-2575","article-title":"Clinical review 1: Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis","volume":"95","author":"Fernandez-Balsells","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032601012888500_bib27","first-page":"397","article-title":"Safety and efficacy of testosterone gel in the treatment of male hypogonadism","volume":"4","author":"Lakshman","year":"2009","journal-title":"Clin Interv Aging"},{"key":"2024032601012888500_bib28","first-page":"2839","article-title":"Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men","volume":"85","author":"Wang","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032601012888500_bib29","volume-title":"Efficacy and safety of Androgel in the treatment of hypogonadal and low testosterone men with type 2 diabetes (NCT00141492)","year":"2012"},{"key":"2024032601012888500_bib30","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/01.ju.0000132389.97804.d7","article-title":"Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone","volume":"172","author":"Shabsigh","year":"2004","journal-title":"J Urol"},{"key":"2024032601012888500_bib31","first-page":"24","volume-title":"Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre","author":"The Uppsala Monitoring Centre","year":"2000"},{"key":"2024032601012888500_bib32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1210\/jc.2009-1251","article-title":"Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: A randomized, double-blind, placebo-controlled study","volume":"95","author":"Srinivas-Shankar","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032601012888500_bib33","first-page":"1001","article-title":"Priapism following testosterone therapy for delayed puberty","volume":"143","author":"Key","year":"1989","journal-title":"Am J Dis Child"},{"key":"2024032601012888500_bib34","first-page":"703","article-title":"Priapism secondary to testosterone administration in the treatment of delayed puberty","volume":"54","author":"Madrid Garcia","year":"2001","journal-title":"Arch Esp Urol"},{"key":"2024032601012888500_bib35","doi-asserted-by":"crossref","first-page":"622 e17","DOI":"10.1016\/j.urology.2005.09.041","article-title":"Testosterone-induced priapism in Klinefelter syndrome","volume":"67","author":"Ichioka","year":"2006","journal-title":"Urology"},{"key":"2024032601012888500_bib36","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/01.ju.0000049199.37765.c9","article-title":"Testosterone induced priapism in Kallmann's syndrome","volume":"169","author":"Shergill","year":"2003","journal-title":"J Urol"},{"key":"2024032601012888500_bib37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/00365599509180545","article-title":"Priapism, its incidence and seasonal distribution in Finland","volume":"29","author":"Kulmala","year":"1995","journal-title":"Scand J Urol Nephrol"},{"key":"2024032601012888500_bib38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ijir.2011.7","article-title":"Incidence and clinical features of priapism in Japan: 46 cases from the Japanese diagnosis procedure combination database 2006\u20132008","volume":"23","author":"Sugihara","year":"2011","journal-title":"Int J Impot Res"},{"key":"2024032601012888500_bib39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.ju.0000046303.22757.f2","article-title":"Pathophysiology of priapism: Dysregulatory erection physiology thesis","volume":"170","author":"Burnett","year":"2003","journal-title":"J Urol"},{"key":"2024032601012888500_bib40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1743-6109.2011.02288.x","article-title":"New insights into the pathophysiology of sickle cell disease-associated priapism","volume":"9","author":"Bivalacqua","year":"2012","journal-title":"J Sex Med"},{"key":"2024032601012888500_bib41","volume-title":"(sildenafil citrate) tablets [prescribing information]","author":"Viagra\u00ae","year":"2010"},{"key":"2024032601012888500_bib42","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1743-6109.2010.01956.x","article-title":"Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study)","volume":"8","author":"Buvat","year":"2011","journal-title":"J Sex Med"},{"key":"2024032601012888500_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01275152","article-title":"The effects of testosterone on the cavernous tissue and erectile function","volume":"15","author":"Shabsigh","year":"1997","journal-title":"World J Urol"},{"key":"2024032601012888500_bib44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2164\/jandrol.109.009597","article-title":"Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: An 84-week phase III clinical trial","volume":"31","author":"Wang","year":"2010","journal-title":"J Androl"},{"key":"2024032601012888500_bib45","volume-title":"Cobert's manual of drug safety and pharmacovigilance","author":"Cobert","year":"2012","edition":"2nd edition"},{"issue":"suppl C","key":"2024032601012888500_bib46","doi-asserted-by":"crossref","first-page":"C40","DOI":"10.1016\/S0149-2918(98)80007-6","article-title":"Limitations and strengths of spontaneous reports data","volume":"20","author":"Goldman","year":"1998","journal-title":"Clin Ther"},{"key":"2024032601012888500_bib47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: A systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"2024032601012888500_bib48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of under-reporting of adverse drug reactions: A systematic review","volume":"32","author":"Lopez-Gonzalez","year":"2009","journal-title":"Drug Saf"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515303180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515303180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/10\/4\/1151\/48192352\/jsm_10_4_1151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/10\/4\/1151\/48192352\/jsm_10_4_1151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T01:50:52Z","timestamp":1711417852000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/10\/4\/1151\/6940009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,1]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,1]]},"published-print":{"date-parts":[[2013,4,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jsm.12059","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,4]]},"published":{"date-parts":[[2013,4,1]]}}}